The need for radiotherapy (RT) treatment is growing and is estimated to outweigh by 10 times the supply.Therefore,the availability of treatments effective in optimizing the delivery of radiations is a must.We have been developing a proprietary platform which allows a targeted delivery of radiations, and is based upon the interaction between avidin and biotin.The platform relies on two key steps: 1) the "avidination of the tumor", which is accomplished by the injection of such protein at the tumor site, thus creating an artificial receptor;2) the selective uptake of I.V.administered biotinylated radio-therapeutics.So far, two products are being developed using this platform: IART(R) and AvidinOx(R)IAPT(R) (Intraoperative Avidination for Radionuclide Treatment) has been originated in collaboration with the European Oncology Institute in Milan, and is aimed at the adjuvant radiotherapy treatment of Stage Ⅰ/Ⅱ breast cancer patients undergoing Breast Conserving Surgery (BCS).These patients usually receive radiations as the standard adjuvant setting to prevent local recurrences, by means of daily administrations of external beam radiations for up to 6 consecutive weeks, with a significant impact on patients quality of life and on social and medical costs.Currently, there is a major effort by the medical community to deliver such radiations in a shorter period of time (accelerated/hypo-fractionated protocols).IART(R) is a stepwise RT approach, currently in phase Ⅱ, that has been proven to delivery an average of 20 Gy perioperative radiation (using Yttrium 90), thus reducing the need of external beam RT post-discharge and allowing the use of accelerated protocols.This approach translates into a highly specific delivery of radiations on the rumor bed, with benefits in terms of safety, tolerability and tissue cosmetics.Moreover, the number of hospital visits and external beam RT sessions after BCS can be sizeably reduced, with an improvement of patients quality of life and clear economic advantages.Finally, IART(R) could potentially become the sole adjuvant RT needed after BCS of smaller tumors (< 2.0 cm in diameter), as well as the target of other tumors requiring post-surgical or intra-cavitary RT (e.g.pleural, bladder, etc...)AvidinOx(R) is a chemically modified avidin which strpngly binds to tissue proteins, thus constituting an even more eager, stable and long lasting receptor for biotin and biotinylated radio-therapeutics.Preclinical studies have so far proven that AvidinOx(R) possesses several advantages compared to current brachytherapy devices, allowing simpler,more targeted and safer procedures.Potential indications are represented by cancers currently treated with brachitherapy.This platform possesses a high potential to simplify RT procedures, providing an increased selectivity and convenience,while also maintaining the required efficacy.